4:19 PM
 | 
Apr 20, 2018
 |  BC Extra  |  Company News

Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) gained $1.82 (18%) to $12.01 Friday after the company said it had resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing.

In 2015, Alnylam filed a suit in the U.S. Superior Court for the Commonwealth of Massachusetts alleging that Dicerna unlawfully obtained and used trade secrets related to Alnylam’s GalNAc...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >